A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Plaque Psoriasis

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506477-35-00

Acronym

SCD-044-19-14

Enrollment

Registered

2024-02-02

Start date

2024-04-02

Completion date

2025-08-27

Last updated

2024-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

moderate to severe plaque psoriasis

Brief summary

Proportion of subjects with at least 75% improvement in PASI (PASI75) at Week 16

Interventions

DRUGSCD-044 Tablets 0.3mg

DRUGSCD-044 Tablets 0.6mg

DRUGSCD-044 Tablets 1.0mg

DRUGSCD-044 Tablets 0.1mg

DRUGplacebo to match SCD-044 tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Proportion of subjects with at least 75% improvement in PASI (PASI75) at Week 16	—

Countries

Estonia, Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026